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Abstract
Background: Metastasis formation remains an enigmatic process and one of the main questions recently asked is whether
metastases are able to generate further metastases. Different models have been proposed to answer this question;
however, their clinical significance remains unclear. Therefore a computer model was developed that permits comparison of
the different models quantitatively with clinical data and that additionally predicts the outcome of treatment interventions.
Methods: The computer model is based on discrete events simulation approach. On the basis of a case from an untreated
patient with hepatocellular carcinoma and its multiple metastases in the liver, it was evaluated whether metastases are able
to metastasise and in particular if late disseminated tumour cells are still capable to form metastases. Additionally, the
resection of the primary tumour was simulated. The simulation results were compared with clinical data.
Results: The simulation results reveal that the number of metastases varies significantly between scenarios where
metastases metastasise and scenarios where they do not. In contrast, the total tumour mass is nearly unaffected by the two
different modes of metastasis formation. Furthermore, the results provide evidence that metastasis formation is an early
event and that late disseminated tumour cells are still capable of forming metastases. Simulations also allow estimating how
the resection of the primary tumour delays the patient’s death.
Conclusion: The simulation results indicate that for this particular case of a hepatocellular carcinoma late metastases, i.e.,
metastases from metastases, are irrelevant in terms of total tumour mass. Hence metastases seeded from metastases are
clinically irrelevant in our model system. Only the first metastases seeded from the primary tumour contribute significantly
to the tumour burden and thus cause the patient’s death.
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Introduction
Metastases are the main cause of death in cancer patients [1].
As a consequence the control of metastases formation has become
one of the fundamental goals in cancer treatment. In order to treat
metastases formation it is important to understand the processes
underlying the metastatic progression. Extensive research had
been done in this area within the last decades. Despite substantial
insights being gained (e.g. [2–6]) many crucial issues are still open,
some of which are highlighted in several reviews [7–12].
Two major models of metastatic progression have been
developed: the linear and the parallel progression model. In the
linear progression model it is assumed that the primary tumour
undergoes several rounds of genetic alterations and competitive
selection before highly malignant cells are able to disseminate and
seed metastases into distant organs. Since these cells are already
highly malignant, the newly created metastases are also likely able
to spawn further new metastases [13]. The parallel progression
places the dissemination of tumour cells early in the development
of the primary tumour, when the cells have not gained full
malignant potential. During outgrowth to a macroscopic detect-
able metastasis they adapt to the distant sites, which leads to
genetic disparity between primary tumour cells and cells within
metastases. It is even assumed that signals from the primary
tumour might promote the outgrowth from the metastatic site.
Late disseminated tumour cells might be less capable to form
metastases or might not even be relevant for the patient’s death
[13].
Although differing in even fundamental aspects of metastasis
formation, both of those models raise four fundamental questions:
1) When does the dissemination of malignant cells from the
primary tumour starts? 2) Are metastases able to metastasize? 3)
Are late disseminated tumour cells capable to form metastases? 4)
Does the primary tumour support the outgrowth of metastases via
signals?
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versatile tools in doing so as their predictions can be examined and
verified quantitatively. A great variety of mathematical models
have been developed, ranging from very fine-grained ones that
consider very detailed biological and molecular or even genetic
characteristics of individual tumour cells [14] to more descriptive
models that concentrate on the whole process, like number of cells,
size or number of metastases [15–17]. All these so far published
models only describe a specific aspect of malignant progression, e.
g. to model the untreated course [15], to estimate the survival time
[16], to predict drug pharmacokinetics [18,19] or to estimate the
effective radiation dose [20].
We therefore wanted to create a computer model which is able
to describe the entire aspects of the metastatic cascade. It allows us
to model different metastatic characteristics, such as the ability of
metastases to metastasize or a variation of the starting point of
metastasis. It can furthermore simulate the effects of potential
treatment interventions. The computer model is expandable, so
that new forms of therapies can be included.
Based on a case from an untreated patient with hepatocellular
carcinoma (HCC) and multiple metastases in the liver we
investigate two fundamental questions, namely whether metastases
metastasize in general and secondly if late disseminated tumour
cell are capable to form metastases. The results indicate that these
late metastases are at least in this one case of a HCC clinically not
relevant, if the patient is left untreated.
Methods
Mathematical Description
The computer model is based on the mathematical model by
Iwata et al. [15]. Here, the parameter x describes the tumour size
as the number of cells in the tumour. The primary tumour starts as
a single malignant cell at the time t=0 and growths with the rate
g(x). Different growth functions can be applied for g(x), e. g. linear,
exponential, power law or Gompertzian growth. In this work the
Gompertzian growth was used since most tumours exhibit this
behaviour and it fits to the clinical data in this case.
The number of cells in the tumour at time t is given by the
function x(t), which is the solution of:
dx
dt
~g(x), x(0)~1 ð1Þ
Solving equation 1 with the Gompertzian growth rate for g(x), the
number of cells at the time t is given by the following function,
x(t)~b1{e{at
ð2Þ
where b is the size of the tumour at its saturated level and a is the
growth rate constant.
The primary tumour spreads metastases with the colonization
rate b(x). For this rate Iwata et al. assumed the following form:
b(x)~mx a ð3Þ
where m is the colonization constant and a is the fractal dimension
which describes how well the tumour is supplied with blood. The
colonization rate includes only those cells that survive intravasa-
tion, the bloodstream and extravasation and are capable of
founding new metastases.
It is assumed that the metastases growth with the same rate g(x)
as the primary tumour and are also able to spread metastases with
the rate b (x).
Computer Model
The computer model describes the behaviour of malignant cells
in the metastatic progression as presented in detail previously [21].
The computer model is developed as a building kit. It provides
different building blocks, from which different simulation setups
can be assembled. The two most important building blocks are
compartments and events. Compartments describe all organs that
can contain malignant cells, such as the primary tumour, the blood
vessels or the connective tissue of distant organs harbouring
metastases. Compartments can be modelled either continuous or
discrete (Fig. 1). In a continuous compartment all internal
processes are described by mathematical functions. The growth
of the primary tumour or a metastasis is represented by a growth
function while the spread of metastases is represented by a
colonisation rate. The parameter for the growth and colonisation
function can be adapted for each continuous compartment. Even
different growth and colonisation functions can be applied for
different continuous compartments in this simulation setup.
In a discrete compartment all internal processes are modelled
with the help of so called events. An event describes what happens
to a single cell in a compartment at a specific time. Events can be
cell division, apoptosis, intravasation or the creation of a new
metastasis (including extravasation). A discrete compartment can
be understood as a bucket, where cells can be put in and deleted
from. The growth or decrease of the compartment is modelled by
simulating every cell division, apoptosis, intravasation and
extravasation of every cell in the compartment. Events are
processed in order of the time on which they occur. After
processing an event a new event is created which defines what
happens next to the cell in the compartment. Every discrete
compartment owns a set of possible events that can occur in this
specific compartment and every kind of event in this set has a
probability with which it occurs. In this way a discrete
compartment can be parameterized to describe different settings,
like the primary tumour, blood stream or tissues where metastases
will develop.
Discrete compartments are used to simulate a compartment in
detail. Since this detailed simulation is very time consuming,
bigger compartments like the primary tumour or the metastases
are represented by continuous compartments.
This building kit structure of the computer model allows
simulation of a larger number of factors as it is possible with the
analytical model of Iwata et.al. It allows changing the metastatic
behaviour during time course, the simulation of the resection of
the primary tumour and the assignment of different growth rates
for primary tumour and metastases.
The following configuration of compartments and events are
used (see also Fig. 2):
Primary tumour and metastases are modelled as continuous
compartments, the growth of both primary tumour and metastases
being described by eq. 2. The spread of metastases by the primary
tumour and the metastases is described by the colonization
function given in eq. 3. In scenarios where metastases are not able
to metastasize, a colonisation rate of zero is applied for the
metastases. In the scenarios where the ability of late disseminated
cells to form a metastasis is tested, the colonisation rate of the
corresponding tumours is set to zero as soon as they reach a
predefined size. The resection of the primary tumour is simulated
by setting the growth rate and colonisation rate to zero at the day
of the resection.
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Intravasation events are created conforming to the colonization
rate defined in eq. 3. Processing an intravasation event the number
of cells in the bloodstream is increased by one and a new event is
created, which describes the behaviour of the new cell within the
bloodstream. Since the colonisation rate used only includes those
malignant cells that survive in the blood stream and found new
metastases, the set of possible events for the blood stream
compartment includes only the extravasation event. Each
surviving tumour cell in the blood stream extravasates indepen-
dently into the tissue. Most cells remain in the blood for about
60 minutes but divergences of about +/220 minutes are possible.
As a consequence, the cells don’t necessarily leave the blood
stream in the same order they entered it. The dwelling time each
cell remains in the blood stream is computed following a Gaussian
distribution. The values for the mean (60 min) and the standard
deviation (20 min) were determined experimentally. Similar times
were published by Meng et.al. [22]. They estimated a half-life for
circulating tumour cells of 1 or 2.4 hours, resp.
Each scenario was simulated 100 times. After completion of all
simulations of a scenario the mean and standard deviation were
computed. To compute the total tumour mass of the primary
tumour and all metastases a cell mass of 10
212 kg [13,17,20] was
assumed.
It is planned to make the software public available in an
upcoming publication.
Clinical Data
The simulation model was compared to clinical data from a case
of a patient with hepatocellular carcinoma (HCC) [15]. Patients
diagnosed with HCC have poor survival prognosis. The overall
median survival after diagnosis is 10 [23] to 11 [24] month,
respectively. Patients who undergo surgery or a liver transplantat
have the best prognosis with a median survival between 21,6 [25]
and 52 [24] months, while untreated patients have a median
survival of about 2 months [23,25]. Depending on tumour stage at
the time of diagnosis, a longer survival is also possible. In
particular, Okuda Stage I patients have a median survival of 8,3
months, however, also survival times up to 42 months were
observed as well [25].
The patient used to model cancer progression was diagnosed
while still at an early stage. The primary tumour had a size of
1,55610
9 cells at the time of diagnosis and no metastases were
detectable. Later during the course of disease several metastases
were detected in the liver. Chemotherapy was started 639 days
after the first diagnosis. During the time until chemotherapy was
commenced several CT scans were performed. The scans were
performed at days 0 (day of the first diagnosis), 50, 89, 432, 559
and 632. The progression of the metastases can be monitored in
the last three CT images. The number of metastases detected in
Figure 1. Compartment types. Compartments describe all parts that can contain malignant cells, such as primary tumour, blood stream or
metastases and can be modelled in two different ways: In continuous compartments (A) all internal processes are represented by mathematical
functions. The growth of the system is modelled via a growth function and the spread of metastases via a rate function. In a discrete compartment (B)
all internal processes are modelled with the help of events. They describe what happens to a single cell at a specific time within the compartment.
Events can be e.g. cell division, apoptosis, intravasation or the creation of a new metastasis and occur with an assigned probability in the
compartment. Discrete compartments are used to simulate a compartment in detail. Continuous compartments are used to simulate bigger systems
like the primary tumour or metastases.
doi:10.1371/journal.pone.0035689.g001
Figure 2. The simulation configuration used for the simula-
tions. The growth of the primary tumour and metastases are modelled
via the mathematical function x(t) (see eq. 2). The blood stream is
modelled via events. The intravasation events are created conforming
to the colonization rate b(x) (see eq. 3). Executing the intravasation
event, a cell is added to the blood stream and a new event describing
what happens next to this cell is generated. In the simulated scenarios it
is examined whether metastases are able to metastasize (dotted line)
and whether particularly late disseminated tumour cells are capable to
form metastases.
doi:10.1371/journal.pone.0035689.g002
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632, respectively.
With the help of the mathematical model Iwata et al. estimated
the day of the tumour inception to be 678 days prior the first
diagnosis (Fig. 3).
The values of the four parameters of the mathematical model
were determined by fitting the mathematical curves to the clinical
data. The values were: a=0.00286 day
21, b=7.3*10
10,
m=5.3*10
28 (cell day)
21 and a=0.663 [15]. The same values
were used in the computer model and the simulations.
Simulated Scenarios
Six different scenarios were examined in the simulations
(Table 1). In the four scenarios A–D, which are discussed first,
the ability to form metastases was investigated (Fig. 4). In scenario
A both the primary tumour and metastases are able to seed
metastases. In scenario B only the primary tumour is able to seed
metastases. In scenario C, again, the primary tumour and
metastases are both able to metastasise. However, late dissemi-
nated tumour cells lose their ability to form metastases as well. In
scenario D late disseminated tumour cells lose their ability to form
metastases as well, while in contrast to scenario C only the primary
tumour is able to metastasise.
In the scenarios C and D the size of the tumour was used as a
benchmark for the stage of development of the primary tumour
and metastases and therefore for the definition of a late
disseminated tumour cell. Three different sizes were chosen with
regard to the maximum size of the presented case of a HCC
(7.3*10
10 cells). The chosen values are 10
8,1 0
9 and 10
10 cells
(Fig. 4, panels C and D). All cells that were disseminated from
tumours after they reached the corresponding size were no longer
able to generate new metastases and eventually died in the
bloodstream. Hence, these cells had no impact on the further
course of the simulated system. To save simulation time, only those
cells that survived in the bloodstream and formed a metastasis
were considered. Therefore, the process of intravasation and
apoptosis of late disseminated cells was condensed by setting the
colonisation rate to zero after the tumours reached the critical size
of 10
8,1 0
9 and 10
10 cells, resp. It is highly unlikely that in reality
the colonisation rate will abruptly drop from its actual value down
to zero as it is set in these scenarios. To our knowledge there are
no experimental or clinical data available that describe the
dropping of the dissemination rate. Therefore, both extreme cases
(no dropping: scn. A and B, instant dropping: scn. C and D) were
chosen to compare the effects of both extreme cases.
In the scenarios AR and BR a possible treatment, the resection of
the primary tumour, was simulated. In scenario AR primary
tumour and metastases were able to metastasize, whereas in
scenario BR only the primary tumour spreads metastases. For both
scenarios two different time points were chosen for the resection.
The first time point was two days after the first diagnosis, at day
680. To analyse how the fate of the patient would have developed
if the carcinoma had been diagnosed earlier, the second time point
was set about two months before the first diagnosis, at day 620. At
this day the primary tumour had a size of 1,044*10
9 cells (,1 g),
which is about the minimum size for clinical detection of a primary
tumour.
As an approximate benchmark for comparing the different
scenarios in relation to the relevance for the patient, the total
tumour mass of the primary tumour and all metastases was used.
For HCC different staging systems exist, to predict the prognosis of
patients [26]. These staging systems include different factors like
the tumour size, the presence of metastases, the liver function or
the general health status of the patient. Since the computer
simulations do not include information about the liver function
and the general health of the patient and additionally the staging
systems are very vague about the tumour size and number of
metastases in end stage HCC, the total tumour mass was used as a
reference value to predict the survival time of the patient. The
value of 1 kg serves as a benchmark for the total tumour mass
[27]. At this approximate size the cancer leads typically to organ
failure or several systemic processes that cause the patient’s death
[13]. This value of 1 kg refers to tumours that also spread
metastases in organs other than the primary tumour. In the
presented case of a HCC the metastases remain only in the liver,
which implies that the lethal tumour mass might be smaller than
1 kg. But since the exact value is not known for a HCC, the value
of 1 kg was set to compare the different scenarios, while eventually
smaller or larger tumour burden could cause the death of a patient
as well.
Results
Existing clinical data of this case are not sufficient to
determine if metastases are able to metastasize or not
As described in the introduction section it remains unclear, if
metastases are able to metastasize or not. In order to answer this
question, scenarios A and B were simulated in the computer
model. The graphs A and B in Fig. 4 show the cumulative number
of the metastases dependent on the size for the two scenarios,
respectively. The corresponding standard deviations for both
scenarios are shown in Fig. S1 and S2. The size of the metastases is
represented by the number of cells. The graph shows the number
of metastases of the size equal or greater to the chosen value on the
x-axes. The cumulative histograms were computed for the three
days on which the CT scans detected the metastases. The
simulation results of both scenarios show no difference in the range
of the clinical data. Only late in time course and for very small
metastases, i. e. smaller than 10
6 cells the graphs differ noticeably
(Fig. S3). Hence, based on this clinical data it is not decidable
whether in this case of a HCC the metastases were able to
metastasize or not.
Late disseminated tumour cells are capable to form
metastases
As mentioned in the introduction section it is unknown whether
tumour cells disseminated late during the development of the
primary tumour and metastases are still capable to form further
metastases. This question was examined in the modelled scenarios
C and D (Table 1, Fig. 4 panels C and D). In both scenarios cells
that were disseminated from the primary tumour (scn. C and D)
Figure 3. Time line of cancer progress and CT scans. The time
line visualizes the progress of the cancer growth and the CT scans taken
to detect metastases. The upper time dates were determined in
reference to the diagnosis. In the second time line the dates were
adapted in reference to the estimated origin of the primary tumour.
doi:10.1371/journal.pone.0035689.g003
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8,1 0
9
or 10
10 cells, resp., were no longer able to form metastases.
The results of the simulations are shown in Fig. 5, panels C and
D. The corresponding standard deviations for both scenarios are
shown in Fig. S4 and S5. Under the assumption that tumour cells
are no longer able to form metastases if they were disseminated
from a primary tumour larger than 10
8 cells, no metastases occur
at all. Therefore, no corresponding data are shown in the graphs.
Next, it was investigated whether disseminated tumour cells are no
longer capable to form metastases if they disseminated from the
primary tumour or a metastasis larger than 10
9 cells. Comparing
the simulation results for this scenario (dashed lines in Fig. 5,
panels C and D) with the clinical data, it is obvious that the
simulated data does not fit to the clinical reality. Only the data
points of the three biggest metastases of each CT scan fit to the
simulation results, indicating that cells that were disseminated
from the primary tumour or a metastasis larger than 10
9 cells
indeed keep their ability to form a metastasis. Finally, it was
examined whether tumour cells that were disseminated from the
primary tumour or metastases larger than 10
10 cells were unable to
form metastases. The simulation results of this scenario (solid lines
in Fig. 5, panels C and D) were compatible with the clinical data,
indicating that it might be possible that cells that were
disseminated from the primary tumour or metastasis larger than
10
10 cells were not longer able to form metastases. But since the
clinical data did not cover the whole range of metastases sizes, it
might also be possible that they keep the ability to form a
metastasis after the tumour had reached this size. As in the
comparison of scenario A and B, the simulation results of the
scenario C (metastases do metastasise) and D (metastases do not
metastasise) show no differences within the range of the clinical
data. Differences were only seen late during time course and for
very small metastases (,10
6 cells).
Significant differences in the number of metastases
Figure 6 shows the development of the total tumour mass and
the number of metastases during the course of the disease. As
described above the value of 1 kg serves as a benchmark for
comparing the different scenarios in relation to the relevance for
the patient. The day on which the total tumour mass of 1 kg is
reached is marked with a dotted line. The number of metastases at
this time point significantly varied between the four scenarios A–D
(see Table 2). Especially between the scenarios where metastases
are able to metastasize (A and C) and where they are not (B and D)
the differences were very large. In scenario A 4402 metastases and
in scenario B 501 metastases existed at the day the total tumour
mass of 1 kg was reached, leading to a total difference of 3901
metastases. In scenario C the number of metastases is 2131, while
in scenario D the number of metastases at the day the total tumour
mass of 1 kg is reached is 38, leading to a difference of 2093
metastases.
Total tumour mass is unaffected if metastases do
metastasize or not
In contrast to the large differences in the number of metastases,
the time reaching a total tumour mass of 1 kg differed only very
little. In scenario A it is reached at day 1728 while in scenario B it
is reached at day 1740. This accounts for a difference of only 12
days. In contrast the number of metastases varied about 3901
metastases. In the scenarios C and D the day of reaching a total
tumour mass of 1 kg was shifted into the future only by 52 days,
while the number of metastases varied about 2093 metastases.
Metastasis formation is an early event
As already briefly shown in the mathematical analysis of the
patient’s data, the computer simulations showed that in this case of
a HCC metastasis is an early event. In the computer simulations
the first metastasis was seeded at day 496. At this time point the
primary tumour had a size of 1.71286*10
8 cells, which equals to
0.17129 g. At this size the primary tumour is clinically not
detectable, which makes metastasis formation a very early event.
Resection of the primary tumour delays the time of death
To test the relevance of resection of the primary tumour on
metastasis formation, the scenarios AR and BR were examined. Here
the resection of the primary tumour was simulated for two different
points in time. Once, two days after the diagnosis and secondly
around two months before the first diagnosis, when the primary
tumour had reached the smallest detectable size of about 1 g (10
9
cells). The simulation results of both scenarios are shown in Fig. 7.
In scenario AR the metastases were able to metastasize. After the
resection of the primary tumour the foundation of new metastases
stagnated, seen as plateaus in the graphs AR1 and AR2 of Fig. 7.
After a time span of about 280 days (resection at day 680) or 350
days (resection at day 620), respectively, the number of metastases
eventually increased again. This increase can be explained by the
fact that the metastases that were seeded before the resection of the
primary tumour are first too small to spawn new metastases. After
they have grown to a certain size they start emitting malignant cells
and therefore are able to seed new metastases. Although the
creationofnew metastasescould not bestopped,the dayofreaching
the lethal tumour mass shifted from 244 days (resection at day 680)
to 290 days (resection at day 620), respectively, into the future.
Thus, the survival time after diagnosis is 43.1 or 44.7 month,
respectively, which fits well with clinical observations [23–25] and is
a clearly noticeable improvement for the patient.
Table 1. Scenarios considered for simulation.
metastases are able to metastasize metastases are not able to metastasize
Late disseminated tumor cells do not lose
the ability to form metastases.
AB
Late disseminated tumor cells lose the ability to
form metastases.
CD
The primary tumor is resected. AR BR
Six scenarios were considered for the computer simulations. In the scenarios A and B it is tested whether metastases do metastasize or not. In the scenarios C and D it is
additionally investigated whether late disseminated tumour cells might be less capable to form metastases. To define the term ‘‘late’’ the size of the primary tumour/
metastases is used as a benchmark. In the scenarios AR and BR the resection of the primary tumour is simulated. Again, once for the case that metastases are able to
metastasise and once for the case that metastases are not able to metastasise.
doi:10.1371/journal.pone.0035689.t001
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scenario metastases were not able to metastasize. Therefore no
new metastases were seeded after the resection of the primary
tumour, since only the primary tumour was able to seed
metastases. The existing metastases keep on growing but are
unable to seed new metastases. After the resection only 8 (resection
at day 680) or 4 (resection at day 620) metastases remain in the
body of the patient. According to the mathematical model from
Iwata et al. (see above), metastases grow with a Gompertzian rate.
This implies that they cannot grow indefinitely but stagnate at a
specific time point. In this particular case of HCC Iwata assumed a
stagnation size of about 7.3*10
10 cells. Hence, since only 8 or 4
metastases are left, this stagnation size would lead to the result that
the lethal tumour mass of 1 kg was never reached in this scenario.
However, this result is unlikely to reflect the clinical situation of the
patient (see discussion).
Discussion
In hepatocellular carcinoma metastases exhibit the same
growth rate as the primary tumour
The mathematical model assumes that primary tumour and
metastases grow with the same rate and seed metastases with the
same rate. Therefore, in the computer simulations the metastases
Figure 4. Scenarios A–D. In scenario A both primary tumour and metastases are able to spread metastases. In scenario B only the primary tumour
is able to spread new metastases. In scenario C and D it is examined whether tumour cells that are disseminated late during the development of the
tumour loose the capability to form metastases. Scenario C in case that metastases metastasise and scenario D in case that metastases do not
metastasise. The size of the tumour is used as a benchmark to estimate the tumour development and therefore the term ‘‘late’’ disseminated tumour
cell. Three sizes are chosen with respect to the maximum tumour size of the presented case of a HCC: 10
8,1 0
9 and 10
10 cells. Cells that are
disseminated into the blood from the primary tumour (scn. C and D) and from metastases (scn. C) after they reached a size of 10
8,1 0
9 or 10
10 cells,
respectively, are no longer able to form a metastasis.
doi:10.1371/journal.pone.0035689.g004
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behaviour as the primary tumour. Comparing the simulation
results and the clinical data (panels A and B in Fig. 4), it seems to
be correct for this particular case of a HCC. This result seems to
be plausible since the primary tumour is growing fast and the
metastases are located in the same organ as the primary tumour.
Further simulations with a higher growth rate for the metastases
(+50% and +100% of the growth rate of the primary tumour)
support this assumption (Fig. S6).
This HCC is a special case of metastasis formation, as
metastases grow in the same organ as the primary tumour does.
It is most likely that this metastasis pattern does not hold true for
all cases of HCC and all kinds of cancers, especially if metastases
grow in other organs than the primary tumour. In other organs
different growth conditions might apply. It is very likely that in this
cases growth rates will differ between the primary tumour and
metastases and probably even between metastases in different
organs, since the microenvironment of the various organs supports
or hampers the growth of metastases differently for different kinds
of cancer as described below.
Only a small amount of metastases is responsible of the
patients death
The results revealed significant differences in the number of
metastases between scenarios where metastases were able to
metastasize and scenarios where they were not. Surprisingly, the
time span until a total tumour mass of 1 kg is reached differs very
little between these two scenarios indicating that this question is
biologically and clinically insignificant for the patients’ outcome.
This little gain in survival is in contrast to the large differences in
the number of metastases, indicating that small metastases are of
no clinical relevance for the patient. In scenario D 38 metastases
are enough to reach a total tumour mass of 1 kg. Hence, not the
total amount of metastases is responsible for the patient’s death but
the first metastases that were able to grow into clinically detectable
macro-metastases.
Figure 5. Case of a hepatocellular carcinoma with multiple metastases in the liver. The circles, squares and triangles represent the clinical
data taken from the patient at the days 1110, 1237 and 1310 after the estimated origin of the primary tumour. The cumulative number of metastases
according to the size of the metastases is shown. Four different scenarios were simulated (see Table 1 and Fig. 4). The results for the scenarios A and B
both fit well with the clinical data. The simulated data differs only in the range of very small metastases (see also Fig. S3). Hence, on the basis of the
available clinical data it is not decidable whether metastases metastasise or not. The simulation results of scenarios C and D clearly show a plateau,
which arises from the fact that the primary tumour reached the plateau size of 10
9 (dashed lines) or 10
10 (solid lines) cells, respectably. All cells that
are disseminated from the primary tumour from now on are no longer able to form a metastasis. In scenario D only the primary tumour is able to
metastasise, so no further metastases are created. The number of metastases stays the same while the existing metastases keep on growing. In
scenario C metastases are able to spread new metastases. As a consequence the number of metastases start rising again, as soon as the first
metastases spread from the primary tumour are large enough to spread metastases themselves. A second plateau is discernible for the case that cells
disseminated from tumours larger than 10
9 cells lose the ability to form metastases (dashed lines). This second plateau indicates that the first
metastasis reached the size of 10
9 cells, too. Such a second plateau cannot be observed for the solid lines since up until day 1310 none of the
metastases reached the critical size of 10
10 cells. In addition to this figure the frequency distribution of the metastases sizes was plotted in Fig. S7.
doi:10.1371/journal.pone.0035689.g005
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results
The simulation results were validated with clinical data from a
fast growing HCC with metastases in the liver only. The computer
model was parameterized to describe this particular case of a
HCC. The results cannot easily be transferred to other
carcinomas, since several studies showed that the distribution of
metastasis to different organs varies between different kinds of
carcinomas, the seed and soil hypothesis [28–30] or even between
different subtypes of one carcinoma entity [31]. Most carcinomas
have a typical set of organs to which they metastasize. These
patterns are due to vascular pathways and the microenvironment
in the organs the disseminated cells end up. Molecular factors like
growth factors, cytokines and signalling cascades influence the
Figure 6. The development of total tumour weight and number of metastases in time. To compare the different scenarios in terms of
relevance for the patient the total tumour mass (blue line), including the primary tumour and all metastases, was computed. The value of the lethal
tumour mass of 1 kg is marked with a dashed line. The number of metastases (red line) was also visualized in the graph. The tumour mass is mapped
to the left y-axes and the number of metastases to the right y-axes. The day on which primary tumour and metastases reach the total mass of 1 kg is
marked with a green dotted line. Again four different scenarios were simulated: A) Metastases are able to metastasize. B) Metastases are not able to
metastasize. C) Primary tumour and metastases metastasize only until they reach a size of 10
10 cells. Metastases are able to metastasize. D) Primary
tumour and metastases metastasize only until they reach a size of 10
10 cells. Metastases are not able to metastasize.
doi:10.1371/journal.pone.0035689.g006
Table 2. Number of metastases on the day of achieving a total tumour mass of 1 kg.
No Treatment Resection
Scenario A B C D AR BR
Day of resection --- --- --- --- 680 620 680 620
Day of reaching lethal tumour mass 1728 1740 1800 1852 1972 2018 --- ---
Number of metastases on that day 4402 501 2131 38 4658 4276 --- ---
The day of reaching a total tumour mass of 1 kg varies from day 1728 in scenario A to day 1852 in scenario D. By resecting the primary tumour this day can be shifted
further into the future. In scenario AR the lethal tumour mass is reached at day 1972 if the primary tumour is resected at day 680 or at day 2018 if the primary tumour is
resected at day 620. In scenario BR the tumour mass of 1 kg is no longer reached. The significant differences in the number of metastases between the scenarios where
metastases are able to metastasize and the scenarios where they are not are particularly remarkable. The difference between scenario A and B is 3901 metastases and
between the scenarios C and D 2093 metastases. In contrast, the day of reaching a total tumour mass of 1 kg was only shifted by 12 or 52 days, respectively, into the
future.
doi:10.1371/journal.pone.0035689.t002
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mutations at the new site may also lead to adaption and therefore
to genetic disparity between the metastases and the primary
tumour and even between metastases in disparate host organs
[33].
So, in a next step the computer model should be applied to
other malignancies, e.g. breast cancer, or other relatively slow
growing tumours, or fast growing malignancies like melanoma, to
test whether the drawn conclusions can be generalized or if not,
which different conclusions can be drawn.
In principle, the computer model is already able to model these
different situations as it allows applying different growth rates for
primary tumour and metastases and even different kinds of
metastases. It also allows defining different probabilities of
spreading into different organs like lung, brain or bone marrow.
However, these modalities will be described in a further
communication.
Stagnation size of the primary tumour is error-prone
The simulation results of scenario BR can lead to the
assumption, that the patient would not die, if metastases are
unable to metastasise and the primary tumour had been resected.
This assumption has to be considered carefully. First, the value of
1 kg represents a rough benchmark for comparing different
scenarios. In the presented case of a HCC the metastases remained
in the liver only, which implies that the lethal tumour mass might
actually be smaller than 1 kg. The actual value might depend on
the liver function and the general health of the patient.
Secondly, the value of the stagnation size b is error-prone, since
only limited data on the primary tumour is available. The
available data indicates that the primary tumour is still in the fast
growing stage of the Gompertz growth and that the detected
metastases were far from the estimated stagnation size of 7.3*10
10
cells. The biggest metastasis measured in all three CT scans had a
size of 8.12*10
9 cells. With this limited data the determination of
the stagnation size b via fitting the theoretical curve to the
observed data is error-prone. Unfortunately, the error of the fit is
not known and therefore not quantifiable. However, computer
simulations with a varied stagnation size b show that higher values
of e.g. +10% (8.08*10
10 cells) or +20% (8.76*10
10 cells) are still
compatible with the observed clinical data (data not shown here).
So, assuming a lower lethal tumour mass and a higher
stagnation size of the primary tumour and metastases it may still
be possible that the patient dies after the resection of the primary
tumour for the scenario that metastases were not able to
metastasise.
Figure 7. Simulated resection of the primary tumour. The resection of the primary tumour was simulated for two different time points. The
first time point is shortly after the initial diagnosis at day 680 (solid lines). The second time point is some time before the first diagnosis at day 620
(dotted lines) simulating early diagnosis e.g. as a result of tumour screening. The cumulative number of metastases according to the size of the
metastases (graphs AR1 and BR1) and the development of the tumour mass and the number of metastases in time (graphs AR2 and BR2) are shown.
After the resection no new metastases are founded for some time. In scenarios AR the number of metastases starts rising again after some time. The
time of death could be shifted to 244 days (resection at day 680) or 290 days (resection at day 620) into the future. In scenario BR no new metastases
are founded after the resection. The existing metastases keep growing, but never reach the benchmark value of 1 kg.
doi:10.1371/journal.pone.0035689.g007
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required
As described in the results section the available clinical data is
not detailed enough to decide whether metastases metastasise or
whether they do not. Within the range of the clinical data the
graphs do not differ (Fig. 5, panels A and B and Fig. S3).
Tumours start to metastasize from a certain minimal size
onwards. Therefore the effect whether metastases do metastasize
can only be observed, after the first metastasis had enough time to
grow and spread itself. Hence, no single value can be attributed for
the size of metastases at which the two scenarios A and B can be
clearly distinguished.
Comparing not only the mean but also the standard deviation, it
is nearly impossible to clearly distinguish between both scenarios at
day 1110. At day 1237 the two scenarios can be separated in the
metastasis size range of 1 till 1000 cells. At day 1310 this range
broadens up till about 10
4 cells. Neglecting the standard deviation
and only comparing the mean values of both scenarios, the range
shifts as follows: day 1110R1–100 cells, day 1237R1–10
5 cells,
day 1310R1–10
6 cells (see Fig. S3).
The question of the capability of late disseminated tumour cells
to form metastases is also not completely answered. Based on the
available clinical data it can be concluded that late disseminated
tumour cells are at least capable to form metastases until the
primary tumour (scn. C and D) or a metastasis (scn. C) reached the
size of 10
10 cells (Fig. 5, panels C and D). Whether cancer cells
disseminated beyond this stage of development loose the capability
to form metastases or not, cannot be decided since the clinical data
is not detailed enough.
To answer these questions, additional data of the presence of
metastases at least smaller than 10
6 cells would be necessary.
Therefore future studies addressing these questions should include
the analysis of smaller metastases.
The computer model can help to understand the
metastatic progression
The aim of the computer model is to facilitate a better
understanding of the processes of metastasis formation. In
particular, this computer model allows to analyse different
scenarios derived from clinical and experimental observations.
Comparing the modelled data with clinical data, it might help to
decide which pattern of metastatic spread applies to the clinical
data.
To be able to do this, it has to be ensured that the computer
model works in accordance with the clinical situation. Therefore
the simulation data was validated with clinical data from a patient
with HCC. The graphs A and B in Fig. 4 show that the simulated
data fits quite well with the clinical data and thereby prove that the
computer model works in accordance with the biology of the
HCC. Based on this finding, different scenarios can be simulated,
like the variation of the metastatic behaviour or different treatment
modalities. Since all these scenarios can be simulated with the
same model, it allows a better comparability of these scenarios.
Such a comparison, as described in this paper, revealed that in this
case of a HCC metastases from metastases are not clinical relevant
if the tumour is left untreated and that also late disseminated
tumour cells are still capable to form metastases.
The capability to simulate different kinds of scenarios is the
particular advantage of the computer model used in this paper. It
was not only designed for a specific part of the metastatic
progression or for a single scenario of the metastatic cascade. On
the contrary, the model can be easily adapted to other aspects of
the metastatic cascade by changing individual parameters or by
changing the growth and colonization functions. This approach
would allow modelling the entire metastatic cascade for many
different tumour entities. In contrast to analytical models such as
described previously [15] these functions can be easily replaced
without recalculating the entire model. It can furthermore be
applied even if no analytical solution exists.
The development of the computer model is still at the
beginning. The model and the software environment is constantly
enhanced and improved but it is already capable to describe a
variety of different types of malignancies.
The next step is to apply the computer model to other cancer
entities and to compare the simulation results with detailed clinical
data, in order to unravel the underlying important biological steps
in cancer metastasis.
Supporting Information
Figure S1 Simulation results of scenario A with mean
and standard deviation. In scenario A primary tumour and
metastases are both able to metastasise. The graph shows the
cumulative number of metastases in relation to the metastasis size.
The thick lines represent the mean for the three days 1110 (green),
1237 (red) and 1310 (blue). The thin black lines above and beneath
each thick line display the standard deviation. The circles, squares
and triangles represent the clinical data taken from the patient at
the days 1110, 1237 and 1310. As can be seen, the clinical data fits
well with the simulation results.
(TIF)
Figure S2 Simulation results of scenario B with mean
and standard deviation. In scenario B only the primary
tumour is able to spread metastases. As in Fig. S1, the graph shows
the cumulative number of metastases in relation to the size of
metastases. The thick lines represent the mean for the three days
1110 (green), 1237 (red) and 1310 (blue). The black lines above
and beneath each thick line display the standard deviation. The
circles, squares and triangles represent the clinical data taken from
the patient at the days 1110, 1237 and 1310. Similar to scenario A
(Fig. S1) the clinical data fits well with the simulation results.
(TIF)
Figure S3 Comparison of scenario A and B. In this figure
the simulation results of the scenarios A and B are displayed in the
same graph. The thick lines represent the mean and the dashed
lines the corresponding standard deviations. The graph clearly
shows that in the range of the clinical data, the two scenarios A
and B are nearly identical. Only in the range of the smaller
metastases and late during the time course the scenarios can be
separated. This is plausible, since tumours have to reach a certain
minimal size, before they start metastasizing. Therefore, the effect
whether metastases do metastasize can only be observed, after the
first metastasis had grown large enough to start spreading
metastases of its own. Including the standard deviation it is nearly
impossible to clearly separate both scenarios at day 1110. At day
1237 both scenarios can be distinguished only for very small
metastases from the size of 1 till 1000 cells. At day 1310 both
scenarios can be clearly distinguished in the metastasis size range
from 1 till 10
4 cells. If only the mean values are compared, the
metastasis size ranges where both scenarios can be separated
change as follows: day 1110R1–100 cells, day 1237R1–10
5 cells,
day 1310R1–10
6 cells (see Fig. S3).
(TIF)
Figure S4 Simulation results of scenario C with mean
and standard deviation. In scenario C both primary tumour
and metastases are able to spread metastases. Cells that are
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they reached a size of 10
9 cells (dashed lines) or 10
10 cells (solid
lines), respectively, lose their ability to form further metastases.
The thick lines represent the mean values, while the thin lines
above and beneath each thick line represent the corresponding
standard deviation. The clinical data does not fit with the dashed
lines, which indicates that cells that are disseminated from tumours
larger than 10
9 cells are still able to form new metastases. In
contrast, the clinical data fits well with the solid lines. This finding
supports the assumption that cells that are disseminated from
tumours larger than 10
9 cells may lose the ability to form
metastases. However, the clinical data is not detailed enough to
definitively decide this question. Clinical data from metastases
smaller than 10
7 cells would be necessary to answer this question.
The plateaus are caused by the primary tumour that reached the
critical size of 10
9 or 10
10 cells, resp. As long as the first metastases
spread by the primary do not reach the minimal size to spread
metastases of their own, no new metastases are created, which
explains the plateau observed. After these metastases start
spreading metastases themselves, the plateau dissolves and the
number of metastases starts rising again. As soon as the first
metastases reach the critical size, too, a second plateau starts to
form which can be observed for the dashed lines (critical size=10
9
cells).
(TIF)
Figure S5 Simulation results of scenario D with mean
and standard deviation. In scenario D the metastases are not
able to metastasise. Similar to scenario C it is investigated whether
cells that are disseminated from the primary tumour and
metastases after they reach a size of 10
9 cells (dashed lines) or
10
10 cells (solid lines), respectively, lose their ability to form
metastases. The thick lines represent mean values, while thin black
lines above and beneath each thick line represent the correspond-
ing standard deviation. As in scenario C the clinical data does not
fit with the dashed lines but with the solid lines. In contrast to
scenario C the observed plateau remains, since only the primary
tumour is able to metastasise. So, as soon as the primary tumour
reaches the critical size of 10
9 or 10
10 cell, resp, no new metastases
are created.
(TIF)
Figure S6 Simulation results of scenario A and B with
higher growth rate for the metastases. The graphs show the
simulation results for the scenarios A (metastases are able to
metastasise) and B (metastases do not metastasise) with a varied
growth rate for the metastases. The solid lines represent the
simulation results for the case that primary tumour and metastases
grow with the same growth rate of a=0.00286 day
21. The dashed
and dotted lines display the simulations results for the case that
metastases grow with a 50% (a=a=0.00429 day
21) or 100%
(a=a=0.00572 day
21), resp., higher growth rate than the primary
tumour. The comparison of the simulation results with the clinical
data clearly shows that in this case of a HCC metastases do not
grow faster than the primary tumour, but that they in fact grow
with the same growth rate as the primary tumour.
(TIF)
Figure S7 Frequency distribution of scenarios A–D. The
graphs display the number of metastases belonging to the size
ranges applied to the x axis. In scenario A much more new created
metastases were present than in scenario B, indicating how much
impact metastasising metastases gain on the number of metastases.
In scenario B much fewer new metastases were created than in
scenario A, since only the primary tumour was able to metastasise.
The higher number of metastases for the bigger metastases sizes at
the days 1237 and 1310 in scenario B results from the
logarithmical division of the metastases size ranges. The graphs
C1 and C2 clearly display the decrease of new created metastases
after the primary tumour reached the critical size of 10
9 (C1)o r
10
10 (C2) cells, respectively, and how the number of new
metastases slowly starts rising again after the first metastases
started spreading metastases of their own. In graph C1 a second
decrease of new created metastases can be observed for the days
1237 and 1310. In contrast to the first decrease, the second
decrease occurs less sudden. This happens because at the time the
first metastasis reached the critical size of 10
9 cells already multiple
metastases are able to spread metastases. In contrast to scenario C
only the primary tumour was able to spread metastases in scenario
D. As a result no new metastases were created after the primary
tumour reached the critical size of 10
9 (D1)o r1 0
10 (D2) cells,
respectively. This fact can be observed in the graphs D1 and D2.
The existing metastases kept on growing, but no new metastases
are created. The total number of metastases is the same for the
three time points (4 in D1 and 38 in D2).
(TIF)
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